VRX-0075 is a preclinical quintuple agonist reported to reduce body weight more than retatrutide in rats. What the ADA 2026 abstract shows and does not.
Written by the Peptide Labs Research Team
VRX-0075 is a preclinical peptide designed to activate five receptors: GLP-1, GIP, glucagon, amylin and calcitonin. A late-breaking abstract for the American Diabetes Association Scientific Sessions 2026 reports it reduced body weight more than retatrutide in obese rats. There are no human data.
Abstract 2839-LB describes a long-acting quintuple agonist. In cell assays its potency at the GLP-1 and GIP receptors and at the glucagon receptor was comparable to retatrutide. At the amylin and calcitonin receptors it was comparable to cagrilintide. In obese rats it outperformed retatrutide at an equivalent molar dose, and its half-life was about 50% longer than semaglutide's. The authors report no observable toxicology findings in a non-regulatory setting.
Unconfirmed. Reports name Volari Therapeutics as developer and describe Lilly-supported research, but we could not verify the authors' affiliations or Lilly's role.
Reports say it had not entered human trials as of June 2026. Rat results often fail to carry over to people. The abstract says nothing about Australian availability. See our incretin comparison and COA guide.
Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public research and gives no use or dosing guidance.
Brenipatide (LY3537031) is Lilly's investigational GIP/GLP-1 agonist, in phase 3 for alcohol use disorder and depression. Registered trials and unknowns.
ResearchMariTide (maridebart cafraglutide) activates GLP-1 and blocks GIP. What Amgen's phase 2 paper reported and where the MARITIME phase 3 programme stands.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides